Alnylam Pharmaceuticals | ALNY - Operating Profit



Alnylam Pharmaceuticals reported $-16199000 in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
Amgen USD 2.66B 1.37B Jun/2025
Arrowhead Research USD -165550000 546.75M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Incyte USD 310.82M 105.66M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
Moderna USD -907000000 143M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD 5.46B 2.06B Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Regeneron Pharmaceuticals USD 1.08B 487.8M Jun/2025
Sanofi EUR 1.71B 851M Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
Takeda JPY 184.56B 259.5B Jun/2025
Tectonic Therapeutic USD -22330000 8.34M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025
Xencor USD -33172000 10.01M Jun/2025